Compare DexCom, Inc. (DXCM) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Ulta Beauty Inc — how do they compare? DexCom, Inc. trades at $90.22 (market cap $33.79B), while Ulta Beauty Inc trades at $538.47 (market cap $23.27B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | ULTA | |
|---|---|---|
Market Cap | $33.79B | $23.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $706.82 |
52-Week Low | $54.84 | $450.75 |
Enterprise Value | $33.24B | $25.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
ULTA Beauty trades at $548.66, down 2.92% on the day, with strong technical momentum indicated by bullish moving averages and key support at $542. Fundamentally, the company maintains robust profitability with 39.33% gross margins and 47.45% ROE, though recent earnings showed mixed results with a Q4 miss. Revenue growth has been consistent, reaching $11.3B in 2025, while analyst sentiment remains positive with 56.53% buy ratings.
The outlook for ULTA remains favorable with a consensus price target of $618.29 offering 12.7% upside potential. Key opportunities include omnichannel expansion and digital growth initiatives, while risks involve margin pressure from rising costs and competitive retail landscape. Institutional ownership trends show continued confidence with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
